A further trial for a most-awaited experimental drug manufactured for treating Alzheimer's disease has been abandoned by Pfizer Inc. as well as Johnson & Johnson, as per a recent report, following the failure of a second trial to show any benefits on patients.

It has been found that the drug bapineuzumab created by the two firms has not only botched to prove promising thus thwarting hopes of thousands of patients. But, it has also personally proved to be a great disappointment for the companies. Immediate fall was seen in their shares following the news.

As per the findings, a previous trial in a similar stage had also failed, which is why the trial in intravenous (IV) form awaiting follow-up extension studies has been extremely disheartening. It is being said that had the drug been passed, it could have addressed the issue of growth of the brain disease. Even the stock of the two groups has faced a significant decline as a consequence of the crash.

Nevertheless, new trials for a new drug named solanezumab being developed by Eli Lilly & Co. are now being planned. Late stage tests would be seen sometime later this year, thus revealing if the drug has potential.